PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
نویسندگان
چکیده
Introduction Uveitis is one of the most serious manifestations of Juvenile Idiopathic Arthritis (JIA), with the potential to cause severe sight-threatening ocular complications. The first line treatment consists of topical and oral steroids with DMARDs therapy for more severe cases, including immunosuppressive and anti-TNFa agents. Abatacept (CTLA-4 immunoglobulin) is a soluble, fully human fusion protein that consists of the extracellular domain of CTLA-4, linked to a modified Fc portion of the human immunoglobulin IgG1, which does not activate the complement. The drug is approved for the treatment of polyarticular JIA.
منابع مشابه
PReS-FINAL-2019: Tuberculosis infection observed in patients receiving biological DMARDs for treatment of juvenile idiopathic arthritis
Results Fourteen of 34 patients (41,2%) received toziliaumab (TOZ), 6 (17,6%) abatacept (ABA), 4 (11,8%) etanercept (ETN), 5 (14,7%) adalimumab (ADA) and 5 (14,7%) infliximab (IFL). Mean treatment duration with biologics was 16,3 (± 10,47), from 3 to 46 months. Different types of TB infection were diagnosed in 6 (17,6%) patients while receiving biological DMARDs. Three of them received treatmen...
متن کاملPReS-FINAL-2138: Abatacept (orencia) in treatment of different types of juvenile idiopathic arthritis
Methods 30 children with JIA were treated with ABA. 23 (77%) pts had polyarticular course of JIA and 7 (23%) systemic JIA. 11 children were diagnosed with acute uveitis (totally 14 affected eyes). 28 (93%) of pts were female. All patients had high degree (III) of disease activity. Mean disease duration was 6,1 ± 3,2 yr. 29 patients previously had an inadequate response to 2 or more non-biologic...
متن کاملSystematic review on treatment of juvenile idiopathic arthritis – associated uveitis
Results Therapy of JIA-associated uveitis is guided by the severity of inflammation and complications. Topical corticosteroids are generally used as the initial treatment. Severe uveitis is commonly treated with immunosuppressive drugs. Methotrexate is presently the first-choice agent. If uveitis is not responding, another immunosuppressive agent or biological is applied. Currently, adalimumab ...
متن کاملAbatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
Introduction Uveitis in JIA can be severe and immunosoppressive therapies may not be sufficient. Anti-TNF-alfa agents (Infliximab, Adalimumab) have been proposed. The percentage of success is different among series and no controlled trials have been published yet. Abatacept, a selective T-cell co-stimulation modulator, has been shown to be a valid alternative to anti-TNF-alfa agents in patients...
متن کاملManaging juvenile idiopathic arthritis-associated uveitis.
Bilateral chronic anterior uveitis is an extra-articular feature of juvenile idiopathic arthritis. Although figures vary, uveitis occurs in approximately 11%-13% of patients with this disease and is most commonly associated with the female gender, oligoarthritis, and presence of antinuclear antibodies. The disease has an insidious onset and is often asymptomatic. Managing patients with juvenile...
متن کامل